ANGPTL4

Across TCGA pan-cancer cohorts, ANGPTL4 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ANGPTL4 data layer compared with 23 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ANGPTL4 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ANGPTL4 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CCRCC, LUAD, and PDAC are the cancer types where ANGPTL4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	OS	Median	All	0.722	0.948	<.001	109	view →
LUAD	OS	Median	II,III,IV	0.393	0.802	<.001	70	view →
PDAC	OS	Tertile	III,IV	0.267	0.968	.002	68	view →
UCEC	DFS	Tertile	II,III,IV	1.000	0.409	.018	24	view →
GBM	OS	Tertile	All	0.225	0.516	.015	11	view →
HNSC	OS	Median	II,III,IV	0.953	1.000	.019	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ANGPTL4–CCRCC (OS)

Open the CCRCC breakdown →